Abstracts tagged "joint damage and rheumatoid arthritis (RA)"

Abstract Number: 1133 • 2014 ACR/ARHP Annual Meeting
Genetic Variants Influencing Joint Damage in Mexican Americans and European Americans with Rheumatoid Arthritis
Rector Arya¹, del Rincon Inmaculada², Vidya S Farook³, Jose Felix Restrepo⁴, Deidre A Winnier⁵, Marcel J Fourcaudot², Daniel Battafarano⁶, Satish Kumar⁷, Marcio AA de Almeida³, Joanne E Curran⁷, Christopher P Jenkinson⁵, John Blangero³, Ravindranath Duggirala⁷ and Agustin Escalante^4,8,9, ¹Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Genetics, Texas Biomedical Research Institute, San Antonio, TX, ⁴Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁵University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁶Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁷Texas Biomedical Research Institute, San Antonio, TX, ⁸Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Joint damage in rheumatoid arthritis (RA) has been shown to be heritable, but knowledge on specific genetic determinants of joint damage in RA is…
Abstract Number: 1066 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Recording of Rheumatoid Arthritis on Death Certificate
Emily Molina¹, Jose Felix Restrepo², Inmaculada del Rincon¹, Daniel Battafarano³ and Agustin Escalante⁴, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁴Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Factors Associated with Recording of Rheumatoid Arthritis on Death Certificates Background/Purpose: Death certificates can be used to study mortality due to a particular disease. However, rheumatoid…
Abstract Number: 451 • 2014 ACR/ARHP Annual Meeting
The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with disease Severity in African-Americans with RA
Maria I. Danila¹, Richard Reynolds², Gordon Wu³, Hemant Tiwari³, William H. Robinson⁴, Jeremy Sokolove⁵, CLEAR Investigators² and S. Louis Bridges Jr.^2,6, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: RA is characterized by the presence of autoantibodies to citrullinated proteins (ACPA) and joint damage. The role of fine specificities of ACPA in radiographic…
Abstract Number: 431 • 2014 ACR/ARHP Annual Meeting
Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy
Maria Greenwald¹, Joann Ball² and Harold Paulus³, ¹Desert Medical Advances, PALM DESERT, CA, ²rheumatology, Desert Medical Advaces, Palm Desert, CA, ³Rheumatology, UCLA, Los Angeles, CA
Background/Purpose: Joint dermal temperature (temp) measured in less than a minute can identify specifically the individual RA patient most likely to develop radiographic change on…
Abstract Number: 1393 • 2014 ACR/ARHP Annual Meeting
Periodontal Disease and Its Impact on Structural Joint Damage in a Rheumatoid Arthritis Peruvian Population
Rocio V. Gamboa-Cardenas^1,2, Manuel F. Ugarte-Gil^1,3, José Quiñones⁴, Francisco Zevallos-Miranda¹, Fiorella Lazo⁴, J. Mariano Cucho-Venegas¹, Risto A. Perich-Campos^1,2, Jose L. Alfaro-Lozano¹, Mariela Medina-Chinchon¹, Zoila Rodriguez-Bellido^1,2, Hugo Torrealva¹ and Cesar A. Pastor-Asurza^1,2, ¹Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, ²Universidad Nacional Mayor de San Marcos, Lima, Peru, ³Universidad Cientifica del Sur, Lima, Peru, ⁴Odontology, Hospital Guillermo Almenara, EsSalud, Lima, Peru
Background/Purpose Periodontal disease (PD) or periodontitis is currently considered an epigenetic determinant of both occurrence and severity of Rheumatoid Arthritis (RA). Common pathophysiological mechanisms like…
Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Michael E. Weinblatt¹, Clifton O. Bingham III², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴, Lenore Noonan³, Daniel Baker⁴ and Rene Westhovens⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…
Abstract Number: 2406 • 2013 ACR/ARHP Annual Meeting
The Relationship Between Anti-Citrullinated Protein Antibodies and Radiographic Damage In African-Americans With Rheumatoid Arthritis
Maria I. Danila¹, Richard J. Reynolds², Stella Aslibekyan³, Ashutosh Tamhane³, Laura B. Hughes⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Doyt L. Conn⁷, Beth L. Jonas⁸, Leigh F. Callahan⁹, Larry W. Moreland¹⁰, Richard D. Brasington¹¹, Edwin A. Smith¹², Ted R. Mikuls¹³, Désirée van der Heijde¹⁴ and S. Louis Bridges Jr.¹⁵, ¹Med/Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Med Div of Clin Imm & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁵VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁸Thurston Arthritis Research Ct, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁹Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC, ¹⁰Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Div of Rheumatology, Washington Univ School of Med, St. Louis, MO, ¹²Dept of Med Div of Rheum, Med Univ of South Carolina, Charleston, SC, ¹³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Joint erosions and joint space narrowing may lead to impaired functional status and disability in rheumatoid arthritis (RA). Autoantibodies to citrullinated proteins (ACPA) are present in…
Abstract Number: 2377 • 2013 ACR/ARHP Annual Meeting
Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Wendy White¹, Patricia Ryan², Xiang Guo³, Dominic Sinibaldi⁴, Gopi Ranganna⁵, Alex Godwood⁶, Didier Saurigny⁶, David Close⁶, Steve Eck⁴, Dee Wilkins¹, Lorin Roskos⁷, Matthew A. Sleeman⁸, Wanying Li⁹, Guy Cavet⁹ and Nadine A. Defranoux⁹, ¹Translational Sciences, MedImmune, Gaithersburg, MD, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune LLC, Gaithersburg, MD, ⁴MedImmune, LLC, Gaithersburg, MD, ⁵Clinical Development, MedImmune, LLC, Cambridge, United Kingdom, ⁶MedImmune, Ltd, Cambridge, United Kingdom, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ⁹Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through effects on macrophages and neutrophils. Mavrilimumab (CAM-3001) is a human monoclonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].